Skip to content

IN-SILICO INVESTIGATION OF HIPTAGE BENGHALENSIS (L.) KURZ FOR THE MANAGEMENT OF SLEEP PARALYSIS

Heemika Sharma, Yogesh Sharma

JOURNAL OF ADVANCE AND FUTURE RESEARCH May 1, 2026 DOI: 10.56975/jaafr.v4i5.509490 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Computational molecular docking study Peer reviewed
Interventions Friedelin Alpha-Amyrin Epifreadelanol Beta-Sitosterol Kaempferol
Key points The authors report that Alpha-Amyrin had the highest affinity for serotonin 5-HT2A (−11.5 kcal/mol) and Friedelin had the highest GABA-A binding (−10.6 kcal/mol), which exceeded that of Diazepam and Fluoxetine. They propose Friedelin and Alpha-Amyrin as promising CNS-active lead compounds for further pharmacological validation.

Abstract

Sleep paralysis is a temporary parasomnia with momentary atonia of the muscles in the body during the sleep-wake changes often accompanied by hallucinations and distress. Although it has an approximate prevalence of about 7.6 percent throughout the world, there is no particular pharmacotherapy that is approved. This paper compares 5 phytoconstituents of Hiptage benghalensis that include Friedelin, Alpha-Amyrin, Epifreadelanol, Beta-Sitosterol and Kaempferol against key neuroreceptors that are involved in sleep paralysis and these include GABA-A (6HUP), Glycine receptor (3JAD), and Serotonin 5-HT 2A (6A93). The SwissADME was used to assess drug-likeness, ADMET profiling was done via pkCSM, docking via CB-Dock2 and validation using DockThor. The highest affinity (−11.5 kcal/mol at 5-HT2A) was seen with Alpha-Amyrin, whereas Friedelin showed the highest GABA-A binding (−10.6 kcal/mol) which was greater than standard drugs Diazepam and Fluoxetine. Terpenoids exhibited high level of blood-brain barrier permeability (log BB > 0). DockThor validation ensured consistency of results within a range of bits of ±2.0 kcal/mol. Promising CNS-active lead compounds are Friedelin and Alpha-Amyrin that may be subjected to additional pharmacological validation.

Explore topics